Revolutionizing Cancer Treatment: Cellectis Presents Breakthrough Results on TALEN®-Edited MUC1 CAR T-Cells for Targeting Triple Negative Breast Cancer at AACR Meeting

At the American Association for Cancer Research (AACR) Annual Meeting 2023, Cellectis, a clinical-stage biotechnology company aiming to develop life-saving cell and gene therapies, presented preclinical data on TALEN®-edited MUC1 CAR T-cells.

The data showed that armored allogeneic MUC1 CAR T-cells have the potential to become a successful treatment option for patients with relapsed and refractory triple negative breast cancer (TNBC), who currently have limited therapeutic options. These findings demonstrate that the use of gene-editing technology could revolutionize cancer treatments and help to save many lives.

MUC1 antigen, which is often overexpressed in many Triple Negative Breast Cancer (TNBC) patients, provides an ideal target for CAR T-cell therapy. This innovative approach offers a promising solution for those suffering from this aggressive form of cancer.

Cellectis’ MUC1 CAR T-cells are a promising option for treating a variety of epithelial cancers, particularly triple negative breast cancer (TNBC). These allogeneic T-cells are designed to target Mucin 1, a protein that is predominantly expressed in cancer cells, with minimal expression in normal epithelium. Furthermore, Cellectis’ MUC1 CAR T-cells feature up to four TALEN®-mediated knockouts and two knock-ins to ensure the highest specificity and efficacy.

We are thrilled to present our preclinical data at AACR which evaluates the efficacy of our CAR T-cell product candidate based on its attributes (knock-out or knock-in). We are confident that allogeneic MUC1 CART-cells can be a powerful option in the treatment of relapsed and refractory triple negative breast cancer.

About Cellectis

Cellectis is a clinical-stage biotechnology company on the cutting edge of gene-editing technology, developing life-saving cell and gene therapies. Its pioneering approach to CAR-T immunotherapies in oncology, which uses off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, has revolutionized the field.

With 23 years of experience and expertise in gene editing, Cellectis also has a platform for therapeutic gene editing in hemopoietic stem cells for various diseases. Headquartered in Paris, France, with locations in New York and Raleigh, North Carolina, Cellectis is listed on the Nasdaq Global Market and on Euronext Growth and is working to develop innovative treatments for diseases with unmet medical needs.

Leave a Comment